Spots Global Cancer Trial Database for A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Official Title: A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Study ID: NCT01716806
Study Description
Brief Summary: This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
Detailed Description: This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as monotherapy and in combination with other agents as frontline therapy. There are 6 parts of the study. The population to be studied includes treatment-naïve patients with classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States
Alaska Urological Institute, Anchorage, Alaska, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
Highlands Oncology Group, Springdale, Arkansas, United States
Providence St Joseph Medical Center, Burbank, California, United States
City of Hope National Medical Center, Duarte, California, United States
Wilshire Oncology Medical Group Inc., Pomona, California, United States
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
Florida Cancer Affiliates, Trinity, Florida, United States
IACT Health, Columbus, Georgia, United States
Georgia Cancer Specialists / Northside Hospital Cancer Institute, Sandy Springs, Georgia, United States
Rush University Medical Center, Chicago, Illinois, United States
Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States
American Oncology Networks LLC, Bethesda, Maryland, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Morristown Medical Center/ Carol G. Simon Cancer Center, Morristown, New Jersey, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
New York Oncology Hematology, P.C., Albany, New York, United States
Columbia University Medical Center, New York, New York, United States
James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Northwest Cancer Specialists, P.C., Tigard, Oregon, United States
Prisma Health, Greenville, South Carolina, United States
Arlington Cancer Center, Arlington, Texas, United States
Texas Oncology - Bedford, Bedford, Texas, United States
Texas Oncology - Presbyterian Cancer Center Dallas, Dallas, Texas, United States
Texas Oncology - Denton South, Denton, Texas, United States
Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States
Houston Methodist Cancer Center, Houston, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Texas Oncology - Longview, Longview, Texas, United States
Texas Oncology - McAllen, McAllen, Texas, United States
Texas Oncology - Seton Williamson, Round Rock, Texas, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Salem, Virginia, United States
Shenandoah Oncology P.C., Winchester, Virginia, United States
Benaroya Research Institute/Virginia Mason Medical Center, Seattle, Washington, United States
Swedish Cancer Institute, Seattle, Washington, United States
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States
University of Alberta / Cross Cancer Institute, Edmonton, Alberta, Canada
London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada
CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
Contact Details
Name: Robert Sims, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
